reported to be potentially capable of correcting bone abnormalities in patients affected by juvenile osteopetrosis.
The best results have been obtained in children transplanted Allogeneic BMT has been reported to be the only curative therapy for children with juvenile autosomal recessusing an HLA-identical relative, whereas those given BMT from an unrelated volunteer or particularly from an HLAive osteopetrosis. We report the case of a 14-month-old child in whom bone resorption was observed after cord partially matched family donor had a lower probability of benefiting from the procedure. 10 Moreover, as neuro-senblood transplantation (CBT). The patient was given CBT from an unrelated newborn matched for five of six sory impairment occurs early during the course of the disease, transplantation of hematopoietic progenitors should HLA antigens. At the time of transplantation, the child presented with neurological symptoms, with feeding be performed as soon as possible.
The use of human umbilical cord blood (CB) hematopoproblems and visual impairment. A successful engraftment of donor hematopoiesis was demonstrated
ietic progenitors from an HLA-identical sibling represents an alternative modality of transplantation, which, since first and the child experienced grade I acute GVHD. Progressive bone clearing was achieved and a bone marrow successfully applied in 1988, is being increasingly employed. 11-13 Advantages of CB transplants (CBT) from trephine demonstrated signs of osteoclast function. Despite full engraftment and bone resorption, neuroa compatible relative include ease and safety of hematopoietic stem cell collection, low risk of viral contamination, logic deterioration did not improve. This experience documents that CBT can promote the correction of juvand at least in view of the currently available evidence, reduced incidence of GVHD. The reduced risk of severe enile osteopetrosis. The shorter time needed both to identify an unrelated donor and to perform the transimmune reactions after CBT and the shorter time needed both to locate a suitable donor and to perform the transplant plant, as well as the lower incidence of GVHD make this procedure more appealing than BMT in children have recently promoted the use of CB progenitor cells from unrelated newborns.
14,15
lacking an HLA-compatible relative. Keywords: cord blood transplantation; malignant osteoWe describe the case of a patient affected by juvenile AR osteopetrosis who underwent successful CBT from an petrosis; bone resorption HLA-partially matched unrelated donor.
Juvenile autosomal recessive (AR) osteopetrosis is a rare Case report disorder of bone metabolism, characterized by deficient osteoclast function, leading to impaired bone resorption.
1,2
The patient, a Caucasian female, was the product of an Patients with this disease have an increased bone density uncomplicated second pregnancy and there was no history resulting in the obliteration of the medullary cavity, which of parental consanguinity. Osteopetrosis was diagnosed at in turn results in extramedullary hematopoiesis which is 4 months of age on the basis of radiological findings of most evident as hepatosplenomegaly, anemia and bleeding marked bony sclerosis (see Figure 1a , b and c). At the time disorders.
1,2 Neurologic symptoms are common and mainly of diagnosis, she had feeding problems and inadequate attributable to mechanical compression of cranial nerves, weight gain. On systemic examination, she revealed hepatooften producing visual impairment. [3] [4] [5] splenomegaly, hypertonia, hyperreflexia and opisthotonic Osteoclasts have been demonstrated to derive from the posture. Optic disks were pale, but the pupils reacted to hematopoietic stem cell 6 and allogeneic BMT has been light and she followed moving objects. Laboratory evaluation indicated a moderate anemia (Hb 94 g/l) and leukocytosis (WBC 24 × 10 9 /l), with circulating erythroblasts Marrow trephine confirmed the diagnosis of osteopetrosis, required assisted ventilation and permanent tracheostomy. Two months later, a CB unit from an unrelated donor matched for five of six HLA-antigens was identified at the New York Blood Center. HLA class I and II antigens serological typing was determined by the standard NIH microlymphocytotoxicity complement-dependent technique. HLA-class II molecular typing (DRB1, DQA1 and DQB1) was performed by the polymerase chain reaction sequence-specific primer technique. 16 The donor was a Caucasian male.
After the patient's parents gave written informed consent CBT was performed when the child was 14 months old. The conditioning regimen comprised: busulfan (18 mg/kg in 16 divided doses over 4 days), thiotepa (10 mg/kg in two divided doses with an interval of 12 h), and cyclophosphamide (120 mg/kg over 2 days). Moreover, the monoclonal antibody Campath-1G was employed in vivo (5 mg/day on days −3 and −2) to prevent graft rejection. Busulfan dosage was adjusted according to the plasma levels of the drug determined after the first dose administration. Busulfan plasma levels were measured by a high performance liquid chromatographic assay previously described by Henner et al. 17 In this specific case, the average plasma concentration at the steady state was below the range which we consider as optimal (500-700 ng/ml). Therefore, the total dose was increased by 15% with respect to an initial value of 16 mg/kg. The CB unit was thawed and washed following the procedure recently described by Rubinstein et al. 18 The number of mononuclear cells and granulocytemacrophage colony-forming units (CFU-GM) transferred per kg of recipient body weight was 16.3 × 10 7 and 39 × 10 3 , respectively (see also Table 1 ). GVHD prophylaxis consisted of a combination of CsA and methylprednisolone (MP). CsA was administered intravenously, starting on day −1, at a dosage of 3 mg/kg/day for the first 28 days, and subsequently per os at a dosage of 8 mg/kg/day for 6 further months after transplant, whereas MP was given at high dosage according to the schedule recently reported by Kurtzberg et al.
14 Granulocyte colony-stimulating factor was employed to reduce the period of neutropenia at a dosage of 5 g/kg/day until neutrophil count recovered over 1 × 10 9 /l. Other details on iesis, the time needed to achieve more than 0.5 × 10 9 /l granulocytes and a platelet count higher than 50 × 10 9 /l being documenting reduced intramedullary space and no signs of experienced grade I skin acute GVHD, which occurred on day +20 during tapering of corticosteroid therapy and At 11 months after transplantation, hepatosplenomegaly is no longer present and the patient has normal blood counts resolved 2 weeks later. No chronic GVHD developed.
As a result of osteoclast engraftment, the radiological and serum calcium levels. Height showed a dramatic catchup growth during the last 6 months. However, neurologic appearance of bone progressively improved and became nearly normal 7 months after CBT (see Figure 2a , b and symptoms are substantially unchanged after CBT and the patient remain hyperreflexic with remarkable feeding probc). Marrow trephine demonstrated clear signs of bone resorption. Serum calcium levels were normal after CBT, lems; pupils do not react to light. Moreover, ophthalmoscopy revealed waxy pallor of the optic disk and prowithout any dietary supplement, and the child did not present the severe hypercalcemic syndrome previously gressive degeneration of the retina. EEG show nonspecific sharp and slow-wave activity. reported in some patients after BMT. 21 The recovery of T cell immunity of the patient, as well as that of natural killer subpopulations, mimicked that described in BMT recipiDiscussion
Malignant osteopetrosis is a heterogeneous congenital disease with variable clinical expression. However, in patients with this disorder, the probability of survival at 6 years has been reported to be about 30% and hematological and/or visual impairment occurring in the 3 first months of life are the most predictive factors of a particularly poor outcome. 1 Even though allogeneic BMT is the only potentially curative treatment of malignant osteopetrosis, its success largely depends on the early availability of an HLA-identical donor. 10 In fact, results of BMT obtained using HLA-disparate family donors have been significantly less satisfactory than those reported for HLA-identical transplants, 10 indicating the need of locating an unrelated matched donor for children with this disorder.
However, for children lacking a suitable sibling, the possibility of finding an HLA-compatible unrelated volunteer is only 30-50% 22,23 and the time required to locate the donor and to perform the transplant can be extremely long. Allogeneic CBT can circumvent these problems, shortening the procurement time of hematopoietic progenitors. Moreover, in this type of transplant there is no risk of donor attrition. These considerations are of particular relevance for children affected by malignant osteopetrosis, in whom a decreased time to acquire a donor graft is crucial to avoid the risk of developing complications or irreversible sequelae, while completing a donor search.
Our report documents in detail the possibility of curing malignant osteopetrosis with cord blood. In fact, our patient experienced complete engraftment and had progressive bone clearing, leading to a near complete normalization of bone structure 7 months after CBT. The achievement of full and stable engraftment of donor hematopoiesis with restoration of osteoclast function is of particular interest, as these patients have an increased risk of rejection, particularly when the donor is an unrelated volunteer and there is some degree of HLA-discrepancy between donor and cation with sequence-specific primers (PCR-SSP) in 2 h: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantations.
